Ferring Drug Patent Portfolio
Ferring owns 10 orange book drugs protected by 38 US patents with Cervidil having the least patent protection, holding only 1 patent. And Nocdurna with maximum patent protection, holding 11 patents. Given below is the list of Ferring's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12458634 | Stabilized Liquid Formations Containing Picosulfate | 27 Jan, 2038 | Active |
| US9827231 | Liquid pharmaceutical composition | 26 Jun, 2034 | Active |
| US10624879 | Liquid pharmaceutical composition | 23 Jun, 2034 | Active |
| US11191753 | Liquid pharmaceutical composition | 23 Jun, 2034 | Active |
| US10695398 | Method of treating prostate cancer with GnRH antagonist | 27 Apr, 2032 | Active |
| US11766468 | Method of treating prostate cancer with GnRH antagonist | 27 Apr, 2032 | Active |
| US11826397 | Method of treating prostate cancer with GnRH antagonist | 27 Apr, 2032 | Active |
| US9415085 | Method of treating prostate cancer with GnRH antagonist | 27 Apr, 2032 | Active |
| US9974826 | Methods comprising desmopressin | 13 Apr, 2030 | Active |
| US8580293 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof | 21 Jan, 2030 | Active |
| US10137167 | Methods comprising desmopressin | 21 May, 2029 | Active |
| US11020448 | Methods comprising desmopressin | 21 May, 2029 | Active |
| US11963995 | Methods comprising desmopressin | 21 May, 2029 | Active |
| US12514898 | Methods Of Treating Prostate Cancer With Gnrh Antagonist | 20 Feb, 2029 | Active |
| US10729739 | Methods of treating prostate cancer with GnRH antagonist | 10 Feb, 2029 | Active |
| US10973870 | Methods of treating prostate cancer with GnRH antagonist | 10 Feb, 2029 | Active |
| US9579359 | Method of treating prostate cancer with GnRH antagonist | 10 Feb, 2029 | Active |
| US10537584 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof | 03 Feb, 2029 | Active |
| US10548904 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof | 03 Feb, 2029 | Active |
| US8450338 | Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof | 10 Oct, 2028 | Active |
| US8481083 | Granular compositions of magnesium oxide and citric acid and uses thereof | 10 Oct, 2028 | Active |
| US7560429 | Orodispersible dosage forms of desmopressin acetate | 02 Feb, 2024 | Expired |
| US7947654 | Pharmaceutical formulations | 29 Dec, 2023 | Expired |
| US8802624 | Methods of treatment using orodispersible desmopressin pharmaceutical formulations | 29 Dec, 2023 | Expired |
| US10307459 | Pharmaceutical formulations of desmopressin | 07 May, 2023 | Expired |
| US9220747 | Methods using desmopressin acetate in orodispersible form | 07 May, 2023 | Expired |
| US9504647 | Pharmaceutical formulations of desmopressin | 07 May, 2023 | Expired |
| US9919025 | Pharmaceutical formulations of desmopressin | 07 May, 2023 | Expired |
| US7022340 | Pharmaceutical composition as solid dosage form and method for manufacturing thereof | 30 Apr, 2023 | Expired |
| US5925730 | GnRH antagonists | 18 May, 2021 | Expired |
| US7300664 | Vaginally administrable progesterone-containing tablets and method for preparing same | 17 Nov, 2019 | Expired |
| US7320800 | Vaginally administrable progesterone-containing tablets and method for preparing same | 17 Nov, 2019 | Expired |
| US7393543 | Vaginally administratable progesterone-containing tablets and method for preparing same | 17 Nov, 2019 | Expired |
| US5674850 | High purity desmopressin produced in large single batches | 23 Dec, 2013 | Expired |
| US5500413 | Process for manufacture of 1-deamino-8-D-arginine vasopressin | 29 Jun, 2013 | Expired |
| US5763407 | High-purity desmopressin produced in large single batches | 29 Jun, 2013 | Expired |
| US5482931 | Stabilized pharmaceutical peptide compositions | 29 Jun, 2013 | Expired |
| US5269321 | Retrievable pessary | 14 Jul, 2012 | Expired |
Latest Legal Activities on Ferring's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ferring.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Information Disclosure Statement (IDS) Filed | 05 Sep, 2025 | US12458634 |
| Mail Notice of Allowance | 03 Sep, 2025 | US12514898 |
| Notice of Allowance Data Verification Completed | 02 Sep, 2025 | US12514898 |
| Information Disclosure Statement considered | 23 Aug, 2025 | US12514898 |
| Disposal for a RCE / CPA / R129 | 19 Aug, 2025 | US12514898 |
| Date Forwarded to Examiner | 19 Aug, 2025 | US12514898 |
| IDS with certification statement | 18 Aug, 2025 | US12514898 |
| Information Disclosure Statement (IDS) Filed | 18 Aug, 2025 | US12514898 |
| Workflow - Request for RCE - Begin | 18 Aug, 2025 | US12514898 |
| Request for Continued Examination (RCE) | 18 Aug, 2025 | US12514898 |
| PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED | 18 Aug, 2025 | US12514898 |
| Terminal Disclaimer Filed | 18 Aug, 2025 | US12514898 |
| Interview Summary - Applicant Initiated - Telephonic | 25 Jul, 2025 | US12514898 |
| Information Disclosure Statement (IDS) Filed | 17 Jul, 2025 | US12458634 |
| Electronic Review | 09 Jul, 2025 | US12458634 |
Ferring's Drug Patent Litigations
Ferring's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 16, 2015, against patent number US9974826. The petitioner , challenged the validity of this patent, with Bjarke Mimer Klein et al as the respondent. Click below to track the latest information on how companies are challenging Ferring's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9974826 | April, 2015 |
Decision
(07 Jun, 2017)
| Bjarke Mimer Klein et al | |
Ferring Drug Patents' Oppositions Filed in EPO
Ferring drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 11, 2014, by Gebro Pharma Gmbh. This opposition was filed on patent number EP09751584A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP13168404A | Dec, 2015 | Generics [UK] Ltd (trading as Mylan) | Revoked |
| EP13168404A | Dec, 2015 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP12165896A | Sep, 2015 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP12165896A | Sep, 2015 | Generics [UK] Limited (trading as Mylan) | Revoked |
| EP09711390A | Jan, 2015 | Generics (UK) Ltd (trading as Mylan) | Revoked |
| EP09751584A | Nov, 2014 | Gebro Pharma GmbH | Patent maintained as amended |
Ferring's Family Patents
Ferring Drug List
Given below is the complete list of Ferring's drugs and the patents protecting them.
1. Cervidil
Cervidil is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5269321 | Retrievable pessary |
14 Jul, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cervidil's drug page
2. Clenpiq
Clenpiq is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12458634 | Stabilized Liquid Formations Containing Picosulfate |
27 Jan, 2038
(11 years from now)
| Active |
| US9827231 | Liquid pharmaceutical composition |
26 Jun, 2034
(8 years from now)
| Active |
| US10624879 | Liquid pharmaceutical composition |
23 Jun, 2034
(8 years from now)
| Active |
| US11191753 | Liquid pharmaceutical composition |
23 Jun, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clenpiq's drug page
3. Ddavp
Ddavp is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7022340 | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
30 Apr, 2023
(2 years ago)
| Expired |
| US5674850 | High purity desmopressin produced in large single batches |
23 Dec, 2013
(12 years ago)
| Expired |
| US5500413 | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
29 Jun, 2013
(12 years ago)
| Expired |
| US5763407 | High-purity desmopressin produced in large single batches |
29 Jun, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ddavp's drug page
4. Ddavp (needs No Refrigeration)
Ddavp (needs No Refrigeration) is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5674850 | High purity desmopressin produced in large single batches |
23 Dec, 2013
(12 years ago)
| Expired |
| US5482931 | Stabilized pharmaceutical peptide compositions |
29 Jun, 2013
(12 years ago)
| Expired |
| US5500413 | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
29 Jun, 2013
(12 years ago)
| Expired |
| US5763407 | High-purity desmopressin produced in large single batches |
29 Jun, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ddavp (needs No Refrigeration)'s drug page
5. Desmopressin Acetate
Desmopressin Acetate is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7022340 | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
30 Apr, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Desmopressin Acetate's drug page
Explore Our Curated Drug Screens
6. Endometrin
Endometrin is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7300664 | Vaginally administrable progesterone-containing tablets and method for preparing same |
17 Nov, 2019
(6 years ago)
| Expired |
| US7320800 | Vaginally administrable progesterone-containing tablets and method for preparing same |
17 Nov, 2019
(6 years ago)
| Expired |
| US7393543 | Vaginally administratable progesterone-containing tablets and method for preparing same |
17 Nov, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Endometrin's drug page
7. Firmagon
Firmagon is protected by 9 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10695398 | Method of treating prostate cancer with GnRH antagonist |
27 Apr, 2032
(6 years from now)
| Active |
| US11766468 | Method of treating prostate cancer with GnRH antagonist |
27 Apr, 2032
(6 years from now)
| Active |
| US11826397 | Method of treating prostate cancer with GnRH antagonist |
27 Apr, 2032
(6 years from now)
| Active |
| US9415085 | Method of treating prostate cancer with GnRH antagonist |
27 Apr, 2032
(6 years from now)
| Active |
| US12514898 | Methods Of Treating Prostate Cancer With Gnrh Antagonist |
20 Feb, 2029
(2 years from now)
| Active |
| US10729739 | Methods of treating prostate cancer with GnRH antagonist |
10 Feb, 2029
(2 years from now)
| Active |
| US10973870 | Methods of treating prostate cancer with GnRH antagonist |
10 Feb, 2029
(2 years from now)
| Active |
| US9579359 | Method of treating prostate cancer with GnRH antagonist |
10 Feb, 2029
(2 years from now)
| Active |
| US5925730 | GnRH antagonists |
18 May, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firmagon's drug page
8. Milprosa
Milprosa is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8580293 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
21 Jan, 2030
(3 years from now)
| Active |
| US10537584 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
03 Feb, 2029
(2 years from now)
| Active |
| US10548904 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
03 Feb, 2029
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Milprosa's drug page
9. Nocdurna
Nocdurna is protected by 11 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9974826 | Methods comprising desmopressin |
13 Apr, 2030
(4 years from now)
| Active |
| US10137167 | Methods comprising desmopressin |
21 May, 2029
(3 years from now)
| Active |
| US11020448 | Methods comprising desmopressin |
21 May, 2029
(3 years from now)
| Active |
| US11963995 | Methods comprising desmopressin |
21 May, 2029
(3 years from now)
| Active |
| US7560429 | Orodispersible dosage forms of desmopressin acetate |
02 Feb, 2024
(2 years ago)
| Expired |
| US7947654 | Pharmaceutical formulations |
29 Dec, 2023
(2 years ago)
| Expired |
| US8802624 | Methods of treatment using orodispersible desmopressin pharmaceutical formulations |
29 Dec, 2023
(2 years ago)
| Expired |
| US10307459 | Pharmaceutical formulations of desmopressin |
07 May, 2023
(2 years ago)
| Expired |
| US9220747 | Methods using desmopressin acetate in orodispersible form |
07 May, 2023
(2 years ago)
| Expired |
| US9504647 | Pharmaceutical formulations of desmopressin |
07 May, 2023
(2 years ago)
| Expired |
| US9919025 | Pharmaceutical formulations of desmopressin |
07 May, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nocdurna's drug page
10. Prepopik
Prepopik is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8450338 | Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof |
10 Oct, 2028
(2 years from now)
| Active |
| US8481083 | Granular compositions of magnesium oxide and citric acid and uses thereof |
10 Oct, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prepopik's drug page